Radius XR™ Named as the CES 2023 Innovation Award Honoree for Wearable Device That Combines Therapy and Diagnostic Capabilities

Radius XR | November 17, 2022 | Read time : 02:00 min

Radius XR™

Today at the CES Unveiled New York event, Radius XR™, a new fashion-forward wearable healthcare technology brand, was named a CES® 2023 Innovation Awards Honoree in both the Digital Health and Virtual & Augmented Reality categories.

Radius was selected from among a record number of submissions to this year’s CES Innovation Awards program. The announcement was made ahead of CES 2023, the influential technology event, happening Jan. 5-8 in Las Vegas, NV.

Radius XR builds on the therapeutic legacy of IrisVision, a leader in digital vision technologies and itself a 2019 CES Innovation Winner. The Radius proprietary XR assistive device brings together—for the first time—multimodal diagnostics, practice management, and patient engagement.

This is a tremendous honor for our new company. It follows on the success of our IrisVision visual assistive device, which has provided a life-changing solution for thousands of individuals living with legal blindness and low-vision conditions. Radius expands on our commitment to vision health by providing the eyecare industry with an easy-to-use wearable device capable of performing standard perimetry tests. Other exams include color vision, visual acuity, contrast sensitivity—a comprehensive suite of standard vision tests. Development of additional exams is ongoing.”

Radius founder and CEO Ammad Khan

Radius enables patients to quickly and easily conduct vision tests with minimal guidance or intervention by the staff. The device’s RadiusExam® software and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards. “By designing our own hardware and software, we’re able to overcome many of the challenges inherent in the off-the-shelf headsets already on the market. Matching visual field strategies, background luminance, stimulus size and dynamic range allows us to mirror the current standards, making it easy and intuitive for clinicians to transition to Radius,” said John Trefethen, Radius Chief Marketing Officer.

In addition, the included Business Suite helps clinicians manage everyday aspects critical to their practice's ongoing success. Features like patient education, staff training and clinician onboarding are now possible inline with the Radius platform.

Radius is the industry’s lightest wearable device and has the look and feel of a pair of stylish sunglasses. The compact, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. With Radius, exams can be conducted anywhere, even in the waiting room, eliminating the need to shuttle patients between machines, which can be challenging for individuals with mobility or vision issues.

The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetics, and design.

The CES 2023 Innovation Awards honorees, including product descriptions and photos, can be found at CES.tech/innovation. Radius will be on display at the Innovation Awards Showcase at CES 2023 in Las Vegas in January.

About Radius XR
The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable XR device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, it adapts to responses to maximize the algorithm's speed.

The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision.


Cuba has been under a U.S. trade embargo for more than 60 years, which has negatively impacted major social and economic services.


Cuba has been under a U.S. trade embargo for more than 60 years, which has negatively impacted major social and economic services.

Related News


East Sussex and VitalHub Announce Licensing Agreement

VitalHub Corp. | January 17, 2023

On January 16, 2023, VitalHub Corp. announced its subsidiary's licensing agreement with East Sussex Healthcare NHS Trust. The subsidiary, Intouch with Health, has licensed its Patient Journey Platform to East Sussex Healthcare, extending the existing relationship between the two companies. East Sussex Healthcare NHS Trust provides acute hospital and community health services to the 525,000 residents of East Sussex and surrounding areas. Most of the Trust's services are provided by two district general hospitals, Eastbourne DGH and Conquest Hospital, which both have 24-hour emergency departments and provide care around the clock. Community teams from the Trust also offer patient care in-home and from several clinics and GP surgeries in East Sussex. East Sussex Healthcare has been a customer of VitalHub subsidiary (Jayex) since 2016, using its 'Enlighten' check-in solutions. By embracing Intouch's Patient Journey Platform, in particular its Intouch Flow Manager, Check-In, and Mobile App solutions, the Trust has chosen to strengthen and broaden its partnership with the company. These tools will help the Trust witness better patient care journeys, improve efficiency and patient satisfaction in care delivery, and enhance resource utilization and operational efficiency. The Patient Journey Platform facilitates NHS Trusts and other healthcare providers to efficiently manage entire patient workflows and enhance flow in outpatient care. The platform processes around 56% of all NHS outpatient attendances annually, handling 55 million outpatient appointments using real-time data and integrated blended pathways to optimize patient flow and assist in more effective patient care. Dan Matlow, CEO of VitalHub Corp., said, "We are pleased to see yet another existing legacy client extend and expand their relationship with VitalHub." He adds, "Our strategic approach to M&A has been predicated on the synergies of our collective product offerings, and our ability to cross-sell and promote organic growth among our install base. This contract provides further ratification of this thesis and of the market demand for our products and services. We look forward to continuing to execute against our growth strategy, offering best-in-class solutions to our customers." (Source – GlobeNewswire) About VitalHub Corp. Toronto-based VitalHub offers technology to health and human services providers, such as hospitals, regional health authorities, long-term care, home health, mental health, and community and social services. Its solutions include electronic health records (EHR), care coordination, case management, operational visibility, patient flow, and DOCit mobile applications. The company aims to optimize outcomes and simplify the patient experience through its software solutions.

Read More


Veradigm® and HeathVerity® Team up to Advance Cardiovascular and Diabetes Care

Veradigm® | February 14, 2023

On February 13, 2023, Veradigm®, a company specializing in healthcare technology and data solutions, and HealthVerity®, a pioneer in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, announced a collaboration progress real-world research and enhanced patient care for those with diabetes and cardiovascular disease. The cooperation enables full interoperability between Veradigm®'s Cardiovascular and Metabolic Registries data and de-identified patient information from HealthVerity® Marketplace, the nation's largest healthcare and consumer data ecosystem. This gives clinical researchers unprecedented access to regulatory-quality, HIPAA-compliant, and research-ready data to improve analytics and treatments. The HealthVerity® IPGE platform integrates technology and real-world data (RWD) to resolve disparate data to unique privacy-protected identities accurately, link them in a HIPAA-compliant manner, and exchange them for a variety of use cases. The largest U.S. outpatient cardiovascular quality improvement registry, the Veradigm® Cardiology Registry, has 102+ million records, 18.9+ million unique patient lives, 13,000 providers, and 4,000 office locations. The registry tracks data on cardiac conditions and records the patient's journey through key measures. In addition, the Veradigm® Metabolic Registry is the first clinical ambulatory registry that tracks and improves prediabetes, diabetes, and cardiometabolic care across primary and specialty care. The registry has 79+ million records representing 13.5+ million unique patient lives, 11,100 providers, and 3,400 office locations. Veradigm® and HealthVerity®'s collaboration uses the industry's most accurate patient matching and identity resolution technology, a vital component of the HealthVerity® IPGE Platform, to help researchers discover more comprehensive longitudinal patient journeys without patient fragmentation characteristic of conventional patient tokenization solutions. About Veradigm® Veradigm® is a healthcare technology company based in Chicago, Illinois. It creates value through a distinct combination of platforms, data, expertise, connectivity, and scale. The Veradigm® Network comprises a dynamic community of solutions and partners offering advanced insights, technology, and data-driven solutions, all of which interact to transform healthcare intelligently. In addition, it employs real-world insights to enhance real-world health and healthcare.

Read More


Aluna and ModuleMD Provide Remote Patient Monitoring to Respiratory Patients

Aluna | February 07, 2023

Aluna, an award-winning linked care platform and at-home spirometer, and ModuleMD, an ONC-certified EHR, announced a partnership on February 6, 2023, to give more patients and providers access to the latest lung health technology. Asthma and cystic fibrosis patients can now effortlessly share their daily lung health variations with their doctor, improving results and reducing attacks through earlier and more frequent interventions. This cooperation will enable easy exchange between physicians, payers, and patients on the Aluna RPM care management platform, with all details incorporated into ModuleMD providers' workflow. Charvi Shetty, Founder and CEO of Aluna, stated, "Close monitoring of asthma and other lung conditions is correlated with better patient outcomes." "Providers seeking to provide the highest quality care with Aluna can do so efficiently and profitably for their practice, now fully integrated with ModuleMD," she added. (Source – Cision PR Newswire) Abhinay Rao, CEO of ModuleMD, remarked, "This partnership represents an important shift in the way clinicians provide patient centered care. For true efficiency, everything needs to be connected to the system of record." He added, "At ModuleMD, our mission is to lead innovation in allergy and pulmonology technology. Through this integration with Aluna, medical practices now have a seamless RPM experience to deliver comprehensive care to patients." (Source – Cision PR Newswire) About Aluna Aluna, a digital spirometry platform certified for use by FDA, gives asthma sufferers and their doctors the ability to monitor their lung function in real-time remotely. The Aluna platform allows practices to offer improved medical care to their patients while simultaneously generating an additional revenue stream through reimbursements for remote patient monitoring (RPM).

Read More